|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FYB1 |
Gene summary for FYB1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FYB1 | Gene ID | 2533 |
| Gene name | FYN binding protein 1 | |
| Gene Alias | ADAP | |
| Cytomap | 5p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0002253 | UniProtAcc | O15117 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2533 | FYB1 | CA_HPV_1 | Human | Cervix | CC | 1.35e-09 | 5.94e-01 | 0.0264 |
| 2533 | FYB1 | CCI_3 | Human | Cervix | CC | 4.65e-06 | 1.10e+00 | 0.516 |
| 2533 | FYB1 | CCII_1 | Human | Cervix | CC | 2.07e-02 | -3.38e-01 | 0.3249 |
| 2533 | FYB1 | Tumor | Human | Cervix | CC | 4.50e-17 | -3.83e-01 | 0.1241 |
| 2533 | FYB1 | H2 | Human | Cervix | HSIL_HPV | 1.48e-12 | -3.50e-01 | 0.0632 |
| 2533 | FYB1 | T1 | Human | Cervix | CC | 9.00e-04 | -2.98e-01 | 0.0918 |
| 2533 | FYB1 | T2 | Human | Cervix | CC | 4.49e-02 | -3.83e-01 | 0.0709 |
| 2533 | FYB1 | T3 | Human | Cervix | CC | 3.79e-02 | -1.60e-01 | 0.1389 |
| 2533 | FYB1 | LZE2D | Human | Esophagus | HGIN | 2.47e-07 | 9.63e-01 | 0.0642 |
| 2533 | FYB1 | LZE4T | Human | Esophagus | ESCC | 9.56e-12 | 7.23e-01 | 0.0811 |
| 2533 | FYB1 | LZE7T | Human | Esophagus | ESCC | 2.07e-15 | 9.47e-01 | 0.0667 |
| 2533 | FYB1 | LZE8T | Human | Esophagus | ESCC | 8.94e-21 | 9.68e-01 | 0.067 |
| 2533 | FYB1 | LZE20T | Human | Esophagus | ESCC | 5.18e-24 | 7.79e-01 | 0.0662 |
| 2533 | FYB1 | LZE22D1 | Human | Esophagus | HGIN | 8.03e-04 | 3.26e-01 | 0.0595 |
| 2533 | FYB1 | LZE24T | Human | Esophagus | ESCC | 4.15e-02 | 2.12e-01 | 0.0596 |
| 2533 | FYB1 | LZE6T | Human | Esophagus | ESCC | 2.80e-24 | 9.54e-01 | 0.0845 |
| 2533 | FYB1 | S028 | Human | Liver | HCC | 1.76e-10 | 6.12e-01 | 0.2503 |
| 2533 | FYB1 | S029 | Human | Liver | HCC | 1.15e-06 | 8.72e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007265910 | Cervix | CC | protein localization to plasma membrane | 73/2311 | 284/18723 | 4.95e-10 | 6.73e-08 | 73 |
| GO:19907788 | Cervix | CC | protein localization to cell periphery | 78/2311 | 333/18723 | 1.22e-08 | 9.73e-07 | 78 |
| GO:00072295 | Cervix | CC | integrin-mediated signaling pathway | 34/2311 | 107/18723 | 1.01e-07 | 5.25e-06 | 34 |
| GO:00027644 | Cervix | CC | immune response-regulating signaling pathway | 97/2311 | 468/18723 | 1.49e-07 | 7.07e-06 | 97 |
| GO:00022533 | Cervix | CC | activation of immune response | 72/2311 | 375/18723 | 8.26e-05 | 1.11e-03 | 72 |
| GO:0002768 | Cervix | CC | immune response-regulating cell surface receptor signaling pathway | 59/2311 | 315/18723 | 6.64e-04 | 6.11e-03 | 59 |
| GO:00508524 | Cervix | CC | T cell receptor signaling pathway | 27/2311 | 123/18723 | 1.93e-03 | 1.42e-02 | 27 |
| GO:000225312 | Cervix | HSIL_HPV | activation of immune response | 40/737 | 375/18723 | 1.12e-08 | 1.30e-06 | 40 |
| GO:000276411 | Cervix | HSIL_HPV | immune response-regulating signaling pathway | 46/737 | 468/18723 | 1.17e-08 | 1.30e-06 | 46 |
| GO:000722913 | Cervix | HSIL_HPV | integrin-mediated signaling pathway | 19/737 | 107/18723 | 3.37e-08 | 2.76e-06 | 19 |
| GO:00027681 | Cervix | HSIL_HPV | immune response-regulating cell surface receptor signaling pathway | 32/737 | 315/18723 | 9.80e-07 | 4.68e-05 | 32 |
| GO:0002429 | Cervix | HSIL_HPV | immune response-activating cell surface receptor signaling pathway | 28/737 | 291/18723 | 1.29e-05 | 4.09e-04 | 28 |
| GO:0002757 | Cervix | HSIL_HPV | immune response-activating signal transduction | 28/737 | 291/18723 | 1.29e-05 | 4.09e-04 | 28 |
| GO:00508513 | Cervix | HSIL_HPV | antigen receptor-mediated signaling pathway | 22/737 | 240/18723 | 2.15e-04 | 3.83e-03 | 22 |
| GO:005085211 | Cervix | HSIL_HPV | T cell receptor signaling pathway | 13/737 | 123/18723 | 1.12e-03 | 1.36e-02 | 13 |
| GO:007265913 | Cervix | HSIL_HPV | protein localization to plasma membrane | 21/737 | 284/18723 | 4.36e-03 | 3.68e-02 | 21 |
| GO:007265920 | Esophagus | HGIN | protein localization to plasma membrane | 66/2587 | 284/18723 | 1.11e-05 | 3.18e-04 | 66 |
| GO:199077818 | Esophagus | HGIN | protein localization to cell periphery | 71/2587 | 333/18723 | 1.05e-04 | 2.24e-03 | 71 |
| GO:0072659110 | Esophagus | ESCC | protein localization to plasma membrane | 193/8552 | 284/18723 | 1.95e-14 | 1.03e-12 | 193 |
| GO:199077819 | Esophagus | ESCC | protein localization to cell periphery | 217/8552 | 333/18723 | 4.08e-13 | 1.88e-11 | 217 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0401512 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
| hsa0513516 | Cervix | CC | Yersinia infection | 39/1267 | 137/8465 | 3.27e-05 | 2.41e-04 | 1.42e-04 | 39 |
| hsa0401513 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
| hsa0513517 | Cervix | CC | Yersinia infection | 39/1267 | 137/8465 | 3.27e-05 | 2.41e-04 | 1.42e-04 | 39 |
| hsa0513526 | Esophagus | ESCC | Yersinia infection | 100/4205 | 137/8465 | 1.80e-08 | 1.59e-07 | 8.12e-08 | 100 |
| hsa05135111 | Esophagus | ESCC | Yersinia infection | 100/4205 | 137/8465 | 1.80e-08 | 1.59e-07 | 8.12e-08 | 100 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |